Megumi Itabashi

Yokohama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia.

Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia.

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: September 08, 2016

Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis.

Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis.

Journal: Internal medicine (Tokyo, Japan)

Published: July 05, 2016

Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia.

Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia.

Journal: Leukemia & lymphoma

Published: June 09, 2016

Favorable prognosis in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia patients following hematopoietic stem cell transplantation.

Favorable prognosis in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia patients following hematopoietic stem cell transplantation.

Journal: Clinical transplantation

Published: March 19, 2016

Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient.

Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient.

Journal: Internal medicine (Tokyo, Japan)

Published: March 18, 2016

Musculoskeletal pain may be associated with imatinib withdrawal syndrome in chronic myeloid leukemia patients.

Musculoskeletal pain may be associated with imatinib withdrawal syndrome in chronic myeloid leukemia patients.

Journal: Leukemia & lymphoma

Published: June 23, 2015

Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.

Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.

Journal: Leukemia & lymphoma

Published: April 11, 2015

Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy.

Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy.

Journal: Leukemia research

Published: August 29, 2014

Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy.

Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy.

Journal: Medical oncology (Northwood, London, England)

Published: June 29, 2014

Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.

Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.

Journal: European journal of haematology

Published: October 21, 2013

European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients.

European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients.

Journal: Cancer science

Published: September 16, 2013

Showing 1-11 of 11

Last Updated: 09/26/2026